Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Canelas Vng – page 44

661 clinical trials in Canelas Vng, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Canelas Vng at a glance
661
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

661 trials in Canelas Vng

Open in trial search

Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Erosive oesophagitis

Not recruiting

Study on Esomeprazole Magnesium for Maintaining Healing of Erosive Esophagitis in Children Aged 1 to 11 Years

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Esomeprazole Magnesium
  • Sponsor:AstraZeneca AB

Polycythaemia vera

Not recruiting

Study on the Effects of Rusfertide (PTG-300) for Patients with Polycythemia Vera

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Rusfertide
  • Sponsor:Takeda Development Center Americas Inc.

Plasma cell myeloma

Not recruiting

Study Comparing Bortezomib, Lenalidomide, and Dexamethasone with Ciltacabtagene Autoleucel for Newly Diagnosed Multiple Myeloma Patients Not Planning Stem Cell Transplant

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Long-Term Study of BI 1015550 for Patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Nerandomilast
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study of [177Lu]Lu-NeoB and Capecitabine for Patients with Advanced Breast Cancer Resistant to Hormone Therapy

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Novartis Pharma AG

Study of Datopotamab Deruxtecan and Pembrolizumab for Patients with Advanced or Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Daiichi Sankyo Inc.

Study on Atezolizumab for Patients with Non-Small Cell Lung Cancer After Chemotherapy

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Dermatitis atopic

Not recruiting

Study on Amlitelimab for Patients Aged 12 and Older with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on Long-Term Safety of Itepekimab for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

B-cell lymphoma+1

Not recruiting

Study on Epcoritamab, Rituximab, and Lenalidomide for Adults with Untreated Follicular Lymphoma

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study of Lenvatinib and Pembrolizumab for Patients with Recurrent or Metastatic Head and Neck Cancer After Platinum and Immunotherapy Treatment

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Canelas Vng

What the registry says about research in the country

01 Cardiovascular Research

Clinical investigations focusing on atherosclerotic cardiovascular disease in patients with end-stage kidney disease, exploring innovative therapeutic approaches for this complex patient population.

  • Cardiovascular Outcomes
  • Inflammation Markers
  • Dialysis Patient Care

The research aims to assess treatment effectiveness through monitoring C-reactive protein levels in dialysis patients, potentially leading to improved cardiovascular outcomes in this high-risk group.

02 Nephrology Studies

Specialized research targeting patients with end-stage kidney disease undergoing maintenance dialysis, evaluating novel therapeutic interventions to address cardiovascular complications.

  • Renal Disease Management
  • Dialysis Therapy
  • Cardiovascular Risk

These trials explore intravenous treatments aimed at reducing inflammation markers and improving overall outcomes in dialysis patients.

03 Inflammatory Biomarkers

Investigation of inflammatory markers in cardiovascular disease, specifically focusing on high-sensitivity C-reactive protein as a key indicator in patients undergoing dialysis.

  • Biomarker Analysis
  • Inflammation Control
  • Treatment Response

The research evaluates various dosing strategies to optimize anti-inflammatory responses in patients with combined cardiovascular and kidney conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.